Biogen, Inc. - Product Pipeline Review - 2015

  • ID: 3243315
  • Company Profile
  • Global Markets Direct
  • Biogen Inc.
1 of 4
Biogen, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Biogen, Inc. - Product Pipeline Review - 2015’, provides an overview of the Biogen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biogen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biogen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biogen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Biogen, Inc.’s pipeline products

Reasons to buy

- Evaluate Biogen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biogen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biogen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biogen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biogen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biogen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Biogen, Inc. Snapshot
Biogen, Inc. Overview
Key Information
Key Facts
Biogen, Inc. - Research and Development Overview
Key Therapeutic Areas
Biogen, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Biogen, Inc. - Pipeline Products Glance
Biogen, Inc. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Biogen, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biogen, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Biogen, Inc. - Drug Profiles
antihemophilic factor (recombinant), fc fusion protein
Product Description
Mechanism of Action
R&D Progress
natalizumab
Product Description
Mechanism of Action
R&D Progress
rituximab
Product Description
Mechanism of Action
R&D Progress
aducanumab
Product Description
Mechanism of Action
R&D Progress
BG-00010
Product Description
Mechanism of Action
R&D Progress
BIIB-023
Product Description
Mechanism of Action
R&D Progress
opicinumab
Product Description
Mechanism of Action
R&D Progress
STX-100
Product Description
Mechanism of Action
R&D Progress
Antibodies to Activate BCAD2 for Systematic Lupus Erthematosus
Product Description
Mechanism of Action
R&D Progress
BG-00001
Product Description
Mechanism of Action
R&D Progress
BIIB-059
Product Description
Mechanism of Action
R&D Progress
BIIB-061
Product Description
Mechanism of Action
R&D Progress
5D-10
Product Description
Mechanism of Action
R&D Progress
BIIB-053
Product Description
Mechanism of Action
R&D Progress
BIIB-054
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Hemophilia A and B
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Neurodegenerative Diseases
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit TDP-43 for Neurodegenerative Diseases
Product Description
Mechanism of Action
R&D Progress
NI-105
Product Description
Mechanism of Action
R&D Progress
NI-205
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize GM-CSFR for Alzheimer's disease and Brain Injury
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Replace Factor VIII for Hemophilia A
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Glucosylceramidase for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
Biogen, Inc. - Pipeline Analysis
Biogen, Inc. - Pipeline Products by Target
Biogen, Inc. - Pipeline Products by Route of Administration
Biogen, Inc. - Pipeline Products by Molecule Type
Biogen, Inc. - Pipeline Products by Mechanism of Action
Biogen, Inc. - Recent Pipeline Updates
Biogen, Inc. - Dormant Projects
Biogen, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
baminercept alfa
clenoliximab
CNF-1010
dexpramipexole dihydrochloride
naxifylline
Biogen, Inc. - Company Statement
Biogen, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Biogen, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Biogen, Inc., Key Information
Biogen, Inc., Key Facts
Biogen, Inc. - Pipeline by Indication, 2015
Biogen, Inc. - Pipeline by Stage of Development, 2015
Biogen, Inc. - Monotherapy Products in Pipeline, 2015
Biogen, Inc. - Partnered Products in Pipeline, 2015
Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Biogen, Inc. - Out-Licensed Products in Pipeline, 2015
Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Biogen, Inc. - Pre-Registration, 2015
Biogen, Inc. - Phase III, 2015
Biogen, Inc. - Phase II, 2015
Biogen, Inc. - Phase I, 2015
Biogen, Inc. - Preclinical, 2015
Biogen, Inc. - Pipeline by Target, 2015
Biogen, Inc. - Pipeline by Route of Administration, 2015
Biogen, Inc. - Pipeline by Molecule Type, 2015
Biogen, Inc. - Pipeline Products by Mechanism of Action, 2015
Biogen, Inc. - Recent Pipeline Updates, 2015
Biogen, Inc. - Dormant Developmental Projects,2015
Biogen, Inc. - Discontinued Pipeline Products, 2015
Biogen, Inc., Other Locations
Biogen, Inc., Subsidiaries
Biogen, Inc., Key Manufacturing Facilities

List of Figures
Biogen, Inc. - Pipeline by Top 10 Indication, 2015
Biogen, Inc. - Pipeline by Stage of Development, 2015
Biogen, Inc. - Monotherapy Products in Pipeline, 2015
Biogen, Inc. - Partnered Products in Pipeline, 2015
Biogen, Inc. - Out-Licensed Products in Pipeline, 2015
Biogen, Inc. - Pipeline by Top 10 Target, 2015
Biogen, Inc. - Pipeline by Top 10 Route of Administration, 2015
Biogen, Inc. - Pipeline by Top 10 Molecule Type, 2015
Biogen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll